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AbsTRACT
Inhibitors of the renin–angiotensin–aldosterone 
(RAAS) system are cornerstones of the management of 
patients with heart failure with reduced left ventricular 
ejection fraction (HFrEF). However, RAAS inhibitors may 
cause decline in renal function and/or hyperkalaemia, 
particularly during initiation and titration, intercurrent 
illness and during worsening of heart failure. There 
is very little evidence from clinical trials to guide the 
management of renal dysfunction. The Renal Association 
and British Society for Heart Failure have collaborated 
to describe the interactions between heart failure, RAAS 
inhibitors and renal dysfunction and give clear guidance 
on the use of RAAS inhibitors in patients with HFrEF. 
During initiation and titration of RAAS inhibitors, testing 
renal function is mandatory; a decline in renal function 
of 30% or more can be acceptable. During intercurrent 
illness, there is no evidence that stopping RAAS inhibitor 
is beneficial, but if potassium rises above 6.0 mmol/L, or 
creatinine rises more than 30%, RAAS inhibitors should 
be temporarily withheld. In patients with fluid retention, 
high doses of diuretic are needed and a decline in renal 
function is not an indication to reduce diuretic dose: 
if the patient remains congested, more diuretics are 
required. If a patient is hypovolaemic, diuretics should 
be stopped or withheld temporarily. Towards end of 
life, consider stopping RAAS inhibitors. RAAS inhibition 
has no known prognostic benefit in heart failure with 
preserved ejection fraction. Efforts should be made to 
initiate, titrate and maintain patients with HFrEF on 
RAAS inhibitor treatment, whether during intercurrent 
illness or worsening heart failure.
bACkgRound
One of the great triumphs of modern medicine is 
the therapy of patients with chronic heart failure 
(CHF) due to reduced left ventricular ejection 
fraction (HFrEF). Treatment with ACE inhibitors 
(ACEIs), angiotensin receptor blockers (ARBs), 
sacubitril/valsartan, beta-blockers and mineralocor-
ticoid receptor antagonists (MRAs) (together with 
appropriate device therapy) increase life expec-
tancy markedly, with the combination of sacu-
bitril/valsartan, beta-blocker and MRA reducing 
all-cause mortality with a HR of 0.37 against 
placebo.1 However, there is frequently a conflict 
between renal function and heart failure therapy. 
Renal dysfunction is extremely common in patients 
with CHF (figure 1) and associated with a worse 
outcome.2 Most of the treatments used for CHF 
can cause worsening renal function.
Anxiety about rises in creatinine (and the asso-
ciated falls in estimated glomerular filtration rate 
[eGFR]) can lead to underprescription of ACEI and 
ARBs. The tendency to withdraw ACEI and ARB 
has been exacerbated by the international adoption 
of the term ‘acute kidney injury’ (AKI) to describe 
acute changes in kidney function3 and by the inclu-
sion of these drugs, which can also protect against 
progressive proteinuric kidney damage, in lists of 
drugs termed ‘nephrotoxic’. The British National 
Formulary and guidelines on chronic kidney disease 
(CKD) published by the National Institute for Health 
and Care Excellence (NICE)4 advise dose reduction 
or even stopping ACEI or ARB if serum creatinine 
rises by >30% without another explanation. The 
NICE heart failure guideline5 recommends regular 
biochemical monitoring but refers to the NICE CKD 
guidelines on how to respond to changes in biochem-
istry. In contrast, the European Society of Cardiology 
heart failure guidelines advise dose reduction or 
withdrawal only if serum creatinine rises by >50% or 
reaches a limit of 266 μmol/L.6 (The arbitrary nature 
of some cut points is shown by the peculiar numbers 
that sometimes appear. They appear less peculiar 
when it is appreciated that they are conversions of 
round numbers of mg/dL.)
The results from clinical trials suggest that fears 
about renal function may be misplaced: in the 
Studies of Left Ventricular Dysfunction (SOLVD) 
trial, 16% of patients in the enalapril arm had a rise 
in serum creatinine >44 μmol/L but so did 12% of 
patients in the placebo arm.7Patients whose renal 
function declines on placebo have a much greater 
increase in their risk of mortality than those whose 
renal function declines on ACEI or ARB.8 However, 
patients are usually excluded from CHF trials if they 
have major renal dysfunction at baseline, making it 
difficult to be certain that the advice is appropriate 
in all patients.
Clinicians receive varying advice from cardiolo-
gists, nephrologists and other physicians. The vari-
ation reflects the lack of robust evidence: designing 
and delivering randomised studies with management 
strategies directed both by changes in renal func-
tion and clinical response would be very complex. 
The different sources of advice can adversely affect 
patient care. Here, we outline consensus recom-
mendations agreed by the Renal Association and the 
British Society for Heart Failure on the management 
of renin–angiotensin–aldosterone system (RAAS) 
blockers in patients with heart failure. Any guidance 
is based on very limited observational evidence and 
cut-offs are necessarily arbitrary.
ChAnges in kidney funCTion duRing 
TReATmenT of Chf
In the absence of evidence from trials, under-
standing how changes in the systemic circulation 
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figure 1 Distribution of estimated glomerular filtration rate (eGFR) 
among 1216 patients with chronic stable heart failure. Data from 
Eur Heart J 2006;27:569–81. AKI, acute kidney injury; CKD, chronic 
kidney disease; HFREF, heart failure with reduced left ventricular 
ejection fraction; MI, myocardial infarction; RAAS, renin–angiotensin–
aldosterone. 
may affect kidney function is important in informing clinical 
recommendations.
effects of systemic blood pressure on glomerular filtration 
rate (gfR)
The normal kidney maintains a stable GFR across a wide range 
of systemic blood pressure due to the effect of an intact RAAS. 
However, in CKD and in long-standing hypertension, the blood 
pressure range for autoregulation is smaller, and GFR becomes 
more pressure dependent, so that a drop in systemic blood 
pressure results in a fall in GFR, without tubular injury.9 RAAS 
inhibitors make GFR much more dependent on systemic arterial 
pressure. A sustained drop in usual blood pressure beyond the 
autoregulatory range causes AKI,10 from which recovery may 
take weeks and may be incomplete. Pre-existing low-flow states, 
including CHF, increase the risk of normotensive AKI.11
effects of renal artery stenosis and intrarenal vascular 
disease
Angiotensin II causes a preferential increase in efferent arteriolar 
tone, helping to maintain GFR when afferent arteriolar pressure 
is low, as in renal artery stenosis and severe generalised intra-
renal arteriosclerosis. In these settings, inhibition of angiotensin 
II production by ACEI or ARB can lead to acute renal failure, 
which is not always reversible.12
effects of venous congestion and fluid overload
Increased systemic venous pressure can cause a decline in GFR 
by increasing renal interstitial pressure. Congestion per se is a 
key driver of change in renal function.13 14 Venous congestion 
also causes an inflammatory response within the renal paren-
chyma. Decongestion by diuretics can thus result in an increase 
in GFR,15 and withdrawal of diuretics from patients with stable 
chronic heart failure can cause tubular injury.15
effects of increased intra-abdominal pressure
Increased intra-abdominal pressure, for instance, due to tense 
ascites, can cause a reduction in GFR in patients with CHF by 
causing functional ureteric obstruction; the precise mechanism 
is unclear.16
effect of neurohormonal activation on gfR
Reduced cardiac output causes neurohormonal activation. 
Sympathetic stimulation causes renal vasoconstriction and a fall 
in GFR. Increased activity of the RAAS causes glomerular arteri-
olar vasoconstriction that is more marked in the efferent than the 
afferent arteriole, helping to preserve GFR. Non-osmotic anti-di-
uretic hormone  (ADH) release contributes to hyponatraemia 
and also to increased urea reabsorption in the collecting duct: 
a disproportionate rise in blood urea is a marker of poor prog-
nosis in patients with acute decompensated heart failure.17 Other 
neurohormones, particularly natriuretic peptides, counteract the 
effects of RAAS activation. GFR is also dependent on the vasodi-
lator effects of prostaglandins. Non-steroidal anti-inflammatory 
drugs can therefore cause a marked fall in GFR.
effects of diuretics on gfR in Chf
Diuretic treatment does not prevent or ameliorate AKI.18 
Although higher diuretic dose in CHF is associated with worse 
outcome,19 the reason is that higher doses of diuretics are a 
marker of more severe heart failure.20 Intravenous diuretics cause 
increased activity of the sympathetic nervous system and the 
RAAS,21 resulting in a fall in GFR, but diuretic-induced decon-
gestion can improve GFR by reducing renal venous pressure.18
Additional effects of RAAs blockade
RAAS blockade might have beneficial renal effects. It reduces 
inflammation, ameliorates experimental AKI and increases 
tubular blood flow.22
heART fAiluRe wiTh ReduCed lefT 
venTRiCulAR ejeCTion fRACTion (hfRef) 
And heART fAiluRe wiTh pReseRved lefT 
venTRiCulAR ejeCTion fRACTion (hfpef): evidenCe foR 
RAAs bloCkAde
Patients with heart failure can be categorised on the basis of 
left ventricular (LV) systolic function into those with HFrEF 
and those with HFpEF.6 In HFrEF, the primary cardiac abnor-
mality is major impairment in LV systolic function. In HFpEF, 
LV systolic function is not necessarily normal but the ejection 
fraction is.
Both ACEIs and MRAs23 reduce mortality and HF hospitalisa-
tions in patients with HFrEF when compared with placebo. The 
combination of the neutral endopeptidase (neprilysin) inhib-
itor, sacubitril, with the ARB, valsartan, reduced mortality and 
HF hospitalisations compared with the previous gold standard, 
enalapril.24 Quality of life is also improved by the RAAS inhibi-
tors. All are at least as effective in patients with mild degrees of 
renal impairment as those with normal renal function (among 
those who met the inclusion criteria of the trials). For example, 
enalapril, spironolactone, eplerenone and sacubitril/valsartan 
in HFrEF all confer similar or greater reduction in mortality 
and heart failure hospitalisation in those with an eGFR below 
60 mL/min/1.73 m2 compared with those with normal renal 
function.24–27
Patients with severe renal disease at baseline were excluded 
from the definitive HFrEF trials. In SOLVD Treatment and 
Randomised Aldactone Evaluation Study (RALES), patients 
with a creatinine of >221 µmol/L were excluded7 23; in 
Prospective Comparison of ARNI with ACEI to Determine 
Impact on Global Mortality and Morbidity in Heart Failure 
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(PARADIGM), those with an eGFR below 30 mL/min/1.73 m2 
were excluded.24 As a result, there is no certainty of benefit 
from RAAS blockers for patients with severely impaired renal 
function.
In contrast to the large body of evidence of the benefit of RAAS 
blockade in HFrEF, there is no convincing evidence of benefit in 
HFpEF. The only trial to suggest possible benefit was the post 
hoc analysis by region of Treatment of Preserved Cardiac Func-
tion Heart Failure with an Aldosterone Antagonist (TOPCAT) 
trial (spironolactone versus placebo in HFpEF).28
 ► There is unequivocal evidence that inhibitors of the RAAS 
improve survival in patients with HFrEF.
 ► All such patients should be offered RAAS inhibitors.
 ► There is no such evidence for patients with HFpEF.
ChAnges in kidney funCTion AfTeR iniTiATion of 
dRug TReATmenT
A decline in renal function is commonly seen in patients when 
they start an ACEI, ARB or sacubitril/valsartan and is usually 
modest. The decline is attributable to loss of renal efferent arte-
riolar vasoconstriction and an acute decrease in intraglomerular 
pressure, with subsequent fall in GFR.29 Renal function may 
actually improve: in Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS), although the average increase 
in creatinine was 44 µmol/L at 2 weeks, in nearly a quarter of 
patients creatinine declined.30 RAAS inhibitors can decrease the 
rate at which renal function subsequently declines, despite an 
apparent initial worsening.
The deterioration in renal function may also indicate haemo-
dynamically significant renal artery stenosis or intrarenal 
vascular disease. For a small proportion of patients, particularly 
those with bilateral renovascular disease, initiation of ACEI/
ARB can result in substantial and irreversible declines in renal 
function or life-threatening hyperkalaemia.12 In those rare cases 
with profound decline in GFR post-RAAS inhibitor, renal artery 
stenosis should be actively sought with decision on revasculari-
sation made on an individual patient basis.
Important questions are: (1) whether there is a level of decline 
in renal function related to ACEI/ARB initiation beyond which 
the risk of continuing treatment outweighs the benefits; and (2) 
whether the risk:benefit balance depends on the indication for 
treatment.
One of the pitfalls in caring for patients with heart failure 
is premature discontinuation of RAAS inhibitors when renal 
function declines during initiation or uptitration of the drugs. 
Worsening renal function is more common in patients treated 
with ACEI and ARB. Among patients with HFrEF, those with 
worse renal function at baseline, and those who have a greater 
decline in renal function during initiation of RAAS inhibitors, 
have a worse prognosis than those who do not; however, they 
gain a greater relative benefit from RAAS inhibitors.8 26 31 32 In 
patients with HFpEF, worse renal function is again associated 
with higher mortality, but in contrast to patients with HFrEF, 
worsening renal function on RAAS inhibitors is associated with 
increased mortality.8
A note on Aki
The term ‘acute kidney injury’ is used to describe changes in 
renal function over a short period of time. The introduction 
of ‘AKI e-alerts’ based on automated recognition of changes in 
creatinine (a rise in serum creatinine from baseline of ≥50% or 
an absolute increment of 26 μmol/L within 48 hours is defined as 
‘stage 1 AKI’) is intended to prompt clinicians to seek and treat 
promptly such reversible causes as sepsis or obstructive nephrop-
athy; in these settings, the e-alerts have proved helpful.33
However, in patients with heart failure, the initial rise in 
creatinine is usually not due to intrinsic kidney injury but to a 
change in haemodynamics. Because patients with heart failure 
commonly have reduced renal function, even a small decline in 
renal function may produce a rise in creatinine large enough to 
trigger an e-alert and the stopping of prognostically vital medi-
cation. An ‘AKI’ alert in a patient starting RAAS inhibitors in a 
patient with HFrEF does not mean the RAAS inhibitor should 
be stopped but should stimulate a careful search for potentially 
reversible causes of renal decline.
 ► A fall in eGFR (and rise in creatinine) is very common after 
initiation of RAAS inhibitors but usually stabilises.
 ► A progressive fall in GFR on RAAS inhibition suggests 
primary renal disease, including extrarenal and intrarenal 
vascular disease.
 ► For patients with HFrEF, the benefit of RAAS inhibitors is 
greater in patients with worsening renal function during 
RAAS inhibition despite their worse prognosis relative to 
those with no decline.
 ► A moderate, asymptomatic decline in renal function is not an 
indication to stop RAAS inhibitors.
 ► Further guidance from the Renal Association and British 
Society for Heart Failure on managing changes in kidney 
function and serum potassium during RAAS inhibition is 
given in table 1 and https:// tinyurl. com/ y7yrlk69.
ChAnges in kidney funCTion duRing inTeRCuRRenT 
illness
Regardless of whether patients are treated with RAAS inhibitors, 
changes in renal function are common during acute intercurrent 
illness; the incidence of AKI is between 7% and 18% of hospi-
talised patients. AKI is a powerful risk marker for poor outcome 
and is strongly associated with an increase in the risk of subse-
quent admission for heart failure.34 Renal function often does 
not to return to baseline level in survivors of AKI, especially in 
those with pre-existing CKD.35
The incidence of AKI as defined by hospital coding is rising 
rapidly, which may reflect a genuine increase or simply greater 
awareness. Conditions associated with the development of AKI 
(such as diabetes and CKD) are also common indications for 
RAAS inhibitors and thus AKI in association with RAAS blockade 
is a common clinical scenario. However, it is not clear that ACEI/
ARB therapy alone is associated with a substantially increased 
risk of AKI.36
When AKI is associated with overt hypovolaemia, hypoten-
sion or sepsis, it is axiomatic that prompt correction of these 
abnormalities will improve outcome. However, the reflex inclu-
sion of patients with HFrEF in treatment algorithms for AKI is 
dangerous. Administration of crystalloids to patients who are 
already fluid overloaded defies common sense. There is no good 
evidence that temporary cessation of RAAS therapy given for 
HFrEF during hospitalisation or perioperatively reduces rates 
of AKI.37 Among patients hospitalised with AKI, treatment with 
ACEI or ARB is associated with a lower risk of death.38
In patients on a RAAS inhibitor, intercurrent illness commonly 
causes AKI, but there is no evidence that stopping the RAAS 
inhibitor is beneficial.
 ► If a patient with HFrEF develops hyperkalaemia (table 2):
 – Potassium ≥5.5 mmol/L, monitor closely, medication re-
view and consider suspending RAAS inhibitor(s).
 – Potassium ≥6.0 mmol/L, stop RAAS inhibitor(s).
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Table 1 Management of RAAS inhibitors in response to change in renal function
Clinical assessment:
 ► Compare with baseline renal function (review series of results).
 ► Assess fluid status: if intravascularly depleted (jugular venous pulse not visible, postural drop in BP and no oedema), consider cautious intravenous fluids.
 ► Interpret BP in the context of usual values (low BP does not necessarily mean patient needs fluid).
 ► Reduce/withdraw RAASI if symptomatic hypotension.
 ► Repeated clinical and biochemical assessment is vital.
 ► Presence of moderate or severe hyperkalaemia may override recommendations based on change in renal function.
 ► In severe renal dysfunction assess for symptoms or uraemia.
Change in renal function compared with baseline
Recommendations for RAAs inhibitors
hfpef (assuming no other prognostic indication). hfRef.
Increase in serum creatinine by <30% Consider stop ACEI/ARB/ARNI
Review MRA according to fluid status.
Continue unless symptomatic hypotension.
Increase in serum creatinine 30%–50% Stop RAAS inhibitor. Consider reducing dose or temporary withdrawal.*
Increase in serum creatinine >50% Stop RAAS inhibitor. Temporarily stop RAAS inhibitor.*
Severe renal dysfunction, for example, eGFR <20 Stop RAAS inhibitor. Stop RAAS inhibitor if symptomatic uraemia irrespective 
of baseline function.
*Reinitiate and/or retitrate when renal function improved in patients with HFrEF.
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced left ventricular ejection 
fraction; HFpEF, heart failure with preserved left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonists; RAAS, renin–angiotensin–aldosterone.
Table 2 Considerations when managing a patient with heart failure who develops hyperkalaemia
serum k+ >5.4 All patients
Check for overdiuresis/hypovolaemia.
non-selective beta-blockers can increase potassium. Review indication (prognostic benefit in hfref but not hfpef) – try to continue in hfref.
stop k supplements.
stop amiloride and triamterene.
stop non-steroidal anti-inflammatory drugs.
stop trimethoprim.
stop sodium substitutes.
Check for digoxin toxicity.
provide low k diet advice.
serum k+ mild hyperkalaemia 5.5–5.9 mmol/l
moderate hyperkalaemia 6.0–
6.4 mmol/l
severe hyperkalaemia
>6.5 mmol/l
Patient clinically well, no AKI Increase frequency of biochemical 
monitoring but do not stop 
RAAS inhibitors. Consider reducing dose.
Stop RAAS inhibitor(s), repeat test
Re-start at lower dose once K+<5.5
Re-start one drug at a time, with 
biochemical monitoring, if the patient was 
previously on a combination of ACEI/ARB/
ARNI plus MRA.
Admit to hospital for immediate K+-lowering 
treatment.
Stop RAAS inhibitor(s).
Repeat blood test 24 hours later.
Restart at lower dose once K+ <5.5
Restart one drug at a time, with biochemical 
monitoring, if the patient was previously on a 
combination of ACEI/ARB/ARNI plus MRA.
Patient clinically unwell with 
sepsis or hypovolaemia and/
or AKI.
Withhold RAAS inhibitors until sepsis/
hypovolaemia corrected, then restart.
Withhold RAAS inhibitor(s) until sepsis/
hypovolaemia corrected, then restart once 
K+ <5.5.
Withhold RAAS inhibitor(s) until sepsis/hypovolaemia 
corrected, then restart once K+ <5.5.
Restart one drug at a time, with biochemical 
monitoring, if the patient was previously on a 
combination of ACEI/ARB/ARNI plus MRA. 
Patient clinically unwell with 
decompensated heart failure 
with/without AKI
Do not withhold RAAS inhibitors. Consider 
reduce dose.
Treat congestion with loop diuretics or 
combination of loop and thiazide diuretics.
Reduce dose of RAAS inhibitor(s) and 
monitor frequently.
Treat congestion with loop diuretics or 
combination of loop and thiazide diuretics.
Withhold RAAS inhibitor(s) and restart at lower dose 
when serum K+ <6.0.
Restart one drug at a time, with biochemical 
monitoring, if the patient was previously on a 
combination of ACEI/ARB/ARNI plus MRA.
ACEI, ACE inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; ARNI angiotensin receptor-neprilysin inhibitor; RAAS, renin–angiotensin–aldosterone; MRA, 
mineralocorticoid receptor antagonist.
 ► If the patient with HFrEF has a rise in creatinine during 
intercurrent illness:
 – By less than 30%, continue RAAS inhibitor(s) but mon-
itor closely.
 – Stop any other medication that may worsen renal func-
tion, including diuretic if clinically appropriate.
 – If by ≥30%, RAAS inhibitor(s) should be stopped.
 ► There must be robust arrangements to make certain that the 
reduced or stopped RAAS inhibitors prescribed for HFrEF 
are reintroduced and/or reuptitrated once the intercurrent 
illness is over.
ChAnges in kidney funCTion duRing woRsening 
heART fAiluRe
The consequences of a decline in renal function in a patient with 
heart failure depend on the clinical setting.39 Patients with hypo-
tension or shock behave differently from those with progressive 
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figure 2 Relationship between change in eGFR during hospitalisation 
and subsequent 60-day hazard for adverse events. Data from 303 
patients in the DOSE trial. J Card Fail 2016;22:753–760. DOSE, Diuretic 
Strategies in Patients with Acute Decompensated Heart Failure; eGFR, 
estimated glomerular filtration rate; ER, emergency room.
figure 3 Management of patients with AKI or worsening renal function who are receiving RAAS inhibitor. Clinical assessment of the individual 
patient is key. In all cases consider original indication for RAAS inhibitor. Major prognostic benefit: HFrEF, post MI and left ventricular systolic 
dysfunction (LVSD), CKD and albuminuria. No/little prognostic benefit: hypertension (other drug options available) and HFpEF. Please refer to table/
text box for management of moderate to severe hyperkalaemia or progressive worsening renal function  (WRF). ACEi, ACE inhibitor; AKI, acute kidney 
injury; ARB, angiotensin receptor blocker; BP, blood pressure; MRA, mineralocorticoid receptor antagonist; RAAS, renin–angiotensin–aldosterone. 
symptoms but who are euvolaemic and differently again from 
those with fluid retention (decompensation with congestion) as 
discussed here.
Congestion
CKD and AKI are undoubtedly associated with a poor prognosis 
in patients with HF,40 but it is far from clear that worsening 
renal function drives the association. Worsening renal function 
is only associated with a worse prognosis in patients whose signs 
of congestion persist at discharge.41 42 It feels intuitively obvious 
that an improvement in eGFR must be related to better outcome, 
but improving renal function is, in fact, associated with worse 
outcome.43 Figure 2 shows data from a post hoc analysis of the 
Diuretic Strategies in Patients with Acute Decompensated Heart 
Failure trial,44 in which patients who were hospitalised with 
congestion were randomised to a high versus low dose intrave-
nous diuretic regimen. Improvement in eGFR at 72 hours was 
independently associated with increased risk of the composite 
end point of death, hospitalisation for HF or visit to the emer-
gency department. The association may reflect inadequate opti-
misation of fluid balance.
Achieving clinical euvolaemia is a fundamental goal to improve 
symptoms and to improve outcome. Patients presenting with 
congestion (unless they are diuretic naive) often need high doses 
of intravenous diuretics to achieve fluid loss.45Patients with fluid 
overload should have their diuretics increased whether or not 
their renal function is impaired (and not stopped as is sometimes 
practice in the hands of non-specialists).
The pharmacological therapy arm of the CARESS study 
provides a useful protocol for managing difficult congestion. 
Doses as high as 30 mg frusemide per hour together with a 
thiazide were used successfully.46 In clinical practice, the initial 
diuretic doses prescribed are often far too low, perhaps driven by 
(an inappropriate) fear of an adverse impact on renal function. 
Clinical assessment is key. If the patient is improving clinically, 
declines in renal function are of secondary importance. Current 
renal function should be assessed in the context of ‘baseline’ 
values (ideally reflecting longer-term serial evaluations).
End-of-life care
When a patient with HF is approaching end of life, symptom 
control overrides treatment with potential prognostic impact. 
Deteriorating renal function is common. Diuretics should be 
titrated to prevent distress from fluid overload, irrespective of 
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renal function. If there is symptomatic hypotension, discontinu-
ation of RAAS blockade is appropriate.
 ► Higher doses of diuretics than are commonly used are 
needed to treat congestion in the fluid overloaded patient.
 ► A decline in renal function is not an indication to reduce 
diuretic dose if the patient remains congested.
 ► Consider stopping RAAS inhibitors towards the end of life.
ConClusions
The interaction between treatment for heart failure and decline in 
renal function is frequently misunderstood and commonly used 
as a reason to withhold potentially life-prolonging therapy. The 
misunderstanding is not helped by referring to RAAS inhibitors 
as ‘nephrotoxic’ drugs, which they most emphatically are not. 
Well-meaning but poorly evidenced recommendations to give 
patients ‘sick day rules’3 have the potential to cause harm when 
patients stop their medication for minor illness (or fail to restart 
them once illness has passed).47 Perhaps of even greater concern 
is inaccurate advice given by bodies such as the Medicines and 
Healthcare products Regulatory Agency, which suggested that 
‘concomitant use of spironolactone with ACEi or ARB is not 
routinely recommended’.48 The combination is, of course, of 
vital importance to patients with symptomatic HFrEF; however, 
close monitoring of renal function and potassium is vital when 
using MRA and other RAAS inhibitor together.49
There is a danger that concerns over renal function may 
prevent patients receiving medication beneficial to their long-
term outcome. While decline in renal function is important and 
may require drugs to be stopped, that should only be after very 
careful consideration of the risks and benefits to the individual 
patient (figure 3).
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